Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS) reported
disappointing results from a Phase 3 VALOR trial of vosaroxin and
cytarabine in patients with first relapsed or refractory acute myeloid
leukemia sending the stock price plummeting $5.18 to close at $1.46.
Disappointing study result for Sunesis Pharmaceuticals
October 06, 2014 at 10:23 AM EDT
